JW중외제약, 535억 품목 판매정지…年실적 타격 적은 이유

The three-month sales suspension for JW Pharmaceutical highlights the long-term regulatory risks associated with past compliance failures, yet its diversified product portfolio and existing distribution inventory are expected to buffer the immediate financial blow. This case underscores the increasing importance of robust internal controls and legal risk management in the pharmaceutical industry as a prerequisite for sustainable growth.